$AEON
AEON Biopharma, Inc.

2022 Q4 Form 10-K Financial Statement

#000110465923023947 Filed on February 22, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.68M
YoY Change
% of Gross Profit
Research & Development $34.75M
YoY Change
% of Gross Profit
Depreciation & Amortization $68.00K
YoY Change
% of Gross Profit
Operating Expenses $2.021M $3.326M
YoY Change 71.78%
Operating Profit -$3.326M
YoY Change 71.78%
Interest Expense $2.580M $10.42M
YoY Change -3.43%
% of Operating Profit
Other Income/Expense, Net $14.19M
YoY Change 39.98%
Pretax Income $721.5K $10.86M
YoY Change 32.47%
Income Tax $629.1K $883.3K
% Of Pretax Income 87.19% 8.13%
Net Earnings $92.39K $9.980M
YoY Change 21.7%
Net Earnings / Revenue
Basic Earnings Per Share -$0.38
Diluted Earnings Per Share $0.00 $0.18
COMMON SHARES
Basic Shares Outstanding 138.8M
Diluted Shares Outstanding 138.8M

Balance Sheet

Concept 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.91K $67.91K
YoY Change -86.35%
Cash & Equivalents $67.91K
Short-Term Investments
Other Short-Term Assets $41.29K $41.29K
YoY Change -87.78%
Inventory
Prepaid Expenses $41.29K
Receivables
Other Receivables
Total Short-Term Assets $109.2K $109.2K
YoY Change -86.93% -86.93%
LONG-TERM ASSETS
Property, Plant & Equipment $431.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $279.4M $279.4M
YoY Change 1.2%
Other Assets $0.00 $0.00
YoY Change -100.0%
Total Long-Term Assets $279.4M $279.4M
YoY Change 1.18% 1.18%
TOTAL ASSETS
Total Short-Term Assets $109.2K $109.2K
Total Long-Term Assets $279.4M $279.4M
Total Assets $279.5M $279.5M
YoY Change 0.92% 0.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.621M $2.621M
YoY Change 312.97%
Accrued Expenses $226.9K $226.9K
YoY Change 13.47%
Deferred Revenue
YoY Change
Short-Term Debt $150.0K $150.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.881M $3.881M
YoY Change 365.02% 365.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.562M $6.562M
YoY Change -61.5%
Total Long-Term Liabilities $6.562M $6.562M
YoY Change -61.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.881M $3.881M
Total Long-Term Liabilities $6.562M $6.562M
Total Liabilities $10.44M $10.44M
YoY Change -41.59% -41.59%
SHAREHOLDERS EQUITY
Retained Earnings -$9.470M
YoY Change -44.17%
Common Stock $14.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $23.00K
YoY Change
Treasury Stock Shares $22.82K
Shareholders Equity -$9.437M $269.1M
YoY Change
Total Liabilities & Shareholders Equity $279.5M $279.5M
YoY Change 0.92% 0.92%

Cashflow Statement

Concept 2022 Q4 2022
OPERATING ACTIVITIES
Net Income $92.39K $9.980M
YoY Change 21.7%
Depreciation, Depletion And Amortization $68.00K
YoY Change
Cash From Operating Activities -$170.3K -$981.4K
YoY Change -34.34%
INVESTING ACTIVITIES
Capital Expenditures $306.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $60.43K $401.9K
YoY Change -100.15%
Cash From Investing Activities $60.43K $401.9K
YoY Change -100.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 150.0K 150.0K
YoY Change -99.95%
NET CHANGE
Cash From Operating Activities -170.3K -981.4K
Cash From Investing Activities 60.43K 401.9K
Cash From Financing Activities 150.0K 150.0K
Net Change In Cash 40.15K -429.5K
YoY Change -186.35%
FREE CASH FLOW
Cash From Operating Activities -$170.3K -$981.4K
Capital Expenditures $306.0K
Free Cash Flow -$1.287M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Liabilities
Liabilities
10443306
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001837607
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 pmgmu Effective Income Tax Rate Reconciliation Reduction In Deferred Underwriting Fee Percent
EffectiveIncomeTaxRateReconciliationReductionInDeferredUnderwritingFeePercent
-0.092
CY2021 pmgmu Effective Income Tax Rate Reconciliation Reduction In Deferred Underwriting Fee Percent
EffectiveIncomeTaxRateReconciliationReductionInDeferredUnderwritingFeePercent
0.000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants
CY2022 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-40021
CY2022 dei Entity Registrant Name
EntityRegistrantName
Priveterra Acquisition Corp
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-3940478
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
300 SE 2nd Street, Suite 600
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Fort Lauderdale
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33011
CY2022 dei City Area Code
CityAreaCode
754
CY2022 dei Local Phone Number
LocalPhoneNumber
220-9229
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Entity Shell Company
EntityShellCompany
true
CY2022 dei Auditor Firm
AuditorFirmId
100
CY2022 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2022 dei Auditor Location
AuditorLocation
Princeton, NJ, USA
CY2021Q2 dei Entity Public Float
EntityPublicFloat
332600000
CY2022Q4 us-gaap Cash
Cash
67909
CY2021Q4 us-gaap Cash
Cash
497412
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41287
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
337812
CY2022Q4 us-gaap Assets Current
AssetsCurrent
109196
CY2021Q4 us-gaap Assets Current
AssetsCurrent
835224
CY2021Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
34619
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
279384429
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
276079687
CY2022Q4 us-gaap Assets
Assets
279493625
CY2021Q4 us-gaap Assets
Assets
276949530
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2620682
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
634585
CY2022Q4 pmgmu Franchise Tax Payable
FranchiseTaxPayable
226936
CY2021Q4 pmgmu Franchise Tax Payable
FranchiseTaxPayable
200000
CY2022Q4 pmgmu Promissory Note Related Party
PromissoryNoteRelatedParty
150000
CY2022Q4 pmgmu Current Deferred Tax Liabilities
CurrentDeferredTaxLiabilities
588899
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
294430
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3880947
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
834585
CY2022Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
669759
CY2021Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
7384800
CY2022Q4 pmgmu Deferred Underwriting Compensations Noncurrent
DeferredUnderwritingCompensationsNoncurrent
5892600
CY2021Q4 pmgmu Deferred Underwriting Compensations Noncurrent
DeferredUnderwritingCompensationsNoncurrent
9660000
CY2021 pmgmu Transaction Costs Other
TransactionCostsOther
655046
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-331144
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
372430
CY2021Q4 us-gaap Liabilities
Liabilities
17879385
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9469643
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16962545
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-9436953
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-16929855
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279493625
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
276949530
CY2022 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3325605
CY2021 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1935943
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-3325605
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-1935943
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6715041
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10712133
CY2022 pmgmu Gain On Forgiveness In Deferred Underwriting Fee Payable
GainOnForgivenessInDeferredUnderwritingFeePayable
3767400
CY2021 pmgmu Transaction Costs Other
TransactionCostsOther
655046
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
3706667
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
79687
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14189108
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10136774
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10863503
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8200831
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
883329
CY2022 us-gaap Net Income Loss
NetIncomeLoss
9980174
CY2021 us-gaap Net Income Loss
NetIncomeLoss
8200831
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
21412
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1199067
CY2021 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
26383165
CY2021 pmgmu Adjustments To Additional Paid In Capital Working Capital Loan Conversion
AdjustmentsToAdditionalPaidInCapitalWorkingCapitalLoanConversion
32000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
8200831
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-16929855
CY2022 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2487272
CY2022 us-gaap Net Income Loss
NetIncomeLoss
9980174
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-9436953
CY2022 us-gaap Profit Loss
ProfitLoss
9980174
CY2021 us-gaap Profit Loss
ProfitLoss
8200831
CY2022 pmgmu Interest Earned On Cash Held In Trust Account
InterestEarnedOnCashHeldInTrustAccount
3706667
CY2021 pmgmu Interest Earned On Cash Held In Trust Account
InterestEarnedOnCashHeldInTrustAccount
79687
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6715041
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10712133
CY2022 pmgmu Gain On Forgiveness Of Deferred Underwriting Fee Payable
GainOnForgivenessOfDeferredUnderwritingFeePayable
3767400
CY2022 pmgmu Increase Decrease Franchise Tax Payable
IncreaseDecreaseFranchiseTaxPayable
321366
CY2021 pmgmu Increase Decrease Franchise Tax Payable
IncreaseDecreaseFranchiseTaxPayable
200000
CY2022 pmgmu Increase Decrease In Deferred Tax Liabilities
IncreaseDecreaseInDeferredTaxLiabilities
588899
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
401925
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1986097
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
613585
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-981428
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1494788
CY2021 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
276000000
CY2022 pmgmu Withdrawal From Trust To Acquire Investments
WithdrawalFromTrustToAcquireInvestments
401925
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-276000000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
270480000
CY2021 pmgmu Net Proceeds From Initial Public Offering
NetProceedsFromInitialPublicOffering
-369212
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7820000
CY2021 pmgmu Proceeds From Working Capital Loan
ProceedsFromWorkingCapitalLoan
100000
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
150000
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
35192
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
73780
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
150000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
277992200
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-429503
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
497412
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
497412
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67909
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
497412
CY2021 pmgmu Deferred Underwriters Discount Payable Charged To Additional Paid In Capital
DeferredUnderwritersDiscountPayableChargedToAdditionalPaidInCapital
9660000
CY2021 pmgmu Conversion Of Working Capital Loans To Private Placement Warrants
ConversionOfWorkingCapitalLoansToPrivatePlacementWarrants
100000
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1 — ORGANIZATION AND BUSINESS OPERATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Organization and General</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Priveterra Acquisition Corp. (the “Company”) is a blank check company incorporated in Delaware on November 17, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (“Business Combination”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On January 5, 2023, in connection with the Business Combination Proposal, a purposed shareholder of the Company filed a complaint in the United States District Court for the Southern District of New York, against the Company and its board of directors, alleging that the registration statement on Form S-4 filed on December 27, 2022 with the SEC omitted material information related to the Business Combination. Since the filing of the complaint, several purported shareholders of the Company have also sent demand letters to the Company’s counsel, similarly alleging that the registration statement filed by the Company on December 27, 2022 with the SEC omitted material information related to the Business Combination and demanding that the Company, its board of directors and/or AEON make supplemental corrective disclosures addressing the alleged deficiencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On November 15, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Priveterra Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of Priveterra Acquisition Corp. The transactions contemplated by the Merger Agreement are intended to serve as the Company’s initial Business Combination. See Note 6 for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had not commenced any operations. All activity for the period from November 17, 2020, the Company’s inception, through December 31, 2022, relates to the Company’s formation and the initial public offering (“IPO”), described below, and identifying a target company for a business combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the IPO and unrealized gains and losses on the change in fair value of it warrants. The Company has selected December 31 as its fiscal year end.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s sponsor is Priveterra Sponsor, LLC, a Delaware limited liability company (the “Sponsor”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company received notice from Guggenheim Securities, LLC, on November 16, 2022 and Wells Fargo Securities, LLC on January 26, 2023, two of the underwriters in the initial public offering, resigning as financial advisors, terminating their financial advisor engagement and waiving any entitlement to any portion of the deferred underwriting commissions payable in connection with the Company’s Initial Public Offering, for a total of $8,694,000 of the deferred fee as waived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company’s IPO was declared effective on February 8, 2021 (the “Effective Date”). On February 11, 2021, the Company consummated an IPO of 27,600,000 units at $10.00 per unit (the “Units”), which includes the full exercise by the underwriters of the over-allotment option to purchase an additional 3,600,000 Units, at $10.00 per Unit, generating gross proceeds of $276,000,000, which is discussed in Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the IPO, the Company consummated the sale of 5,213,333 warrants (the “Private Placement Warrants”), at a price of $1.50 per warrant, which is discussed in Note 4. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, generating gross proceeds of $7,820,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Transaction costs of the IPO amounted to $15,630,212 consisting of $5,520,000 of underwriting fees, $9,660,000 of deferred underwriting fees, and $450,212 of other offering costs. Of the transaction costs, $655,046 is included in offering costs on the statements of operations and $14,975,165 is included in equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Trust Account</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the IPO on February 11, 2021, $276,000,000 ($10.00 per Unit) from the net offering proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”), located in the United States with Continental Stock Transfer &amp; Trust Company acting as trustee and will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (“Investment Company Act”), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its franchise and income tax obligations, if any, the proceeds from the Company’s IPO and the sale of the Private Placement Warrants will not be released from the Trust Account until the earliest of (i) the completion of initial Business Combination, (ii) the redemption of the Company’s public shares if the Company does not complete an initial Business Combination within 24 months from the closing of the IPO, subject to applicable law, or (iii) the redemption of the Company’s public shares properly submitted in connection with a stockholder vote to amend its amended and restated certificate of incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of its public shares if the Company has not consummated an initial business combination within 24 months from the closing of the IPO or with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity. The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could have priority over the claims of the Company’s public stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In connection with the vote at the special meeting of stockholders held on February 10, 2023 (the “Special Meeting”) the holders of 25,597,728 shares of Class A common stock properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.11 per share, for an aggregate redemption amount of approximately $258,793,030.08, resulting in 2,002,272 shares of Class A common stock after redemptions. The trust account balance after the redemption payments are made will be $20,259,152.12.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Initial Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company will provide its public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a stockholder meeting called to approve the initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.00 per share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The shares of common stock subject to redemption are recorded at a redemption value and classified as temporary equity upon the IPO, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Sponsor, officers and directors have agreed to (i) waive their redemption rights with respect to their founder shares and public shares in connection with the completion of the initial Business Combination, (ii) waive their redemption rights with respect to their founder shares and public shares in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation, and (iii) waive their rights to liquidating distributions from the Trust Account with respect to their founder shares if the Company fails to complete the initial Business Combination within the Combination Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 12, 2022, the Company entered into a Business Combination Agreement (the “Business Combination Agreement”) by and among the Company, Priveterra Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and AEON Biopharma, Inc., a Delaware corporation (“AEON”). The Business Combination Agreement provides, among other things, that on the terms and subject to the conditions set forth therein, Merger Sub will merge with and into AEON, with AEON surviving as a wholly owned subsidiary of the Company (the “Merger”). Upon the closing of the Merger (the “Closing”), the Company will change its name to “AEON Biopharma, Inc.” The date on which the Closing actually occurs is hereinafter referred to as the “Closing Date.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company will have 24 months from the closing of the IPO to complete the initial Business Combination (the “Combination Period”). However, if the Company is unable to complete the initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, liquidate and dissolve, subject, in each case, to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.10 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Company’s IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). However, the Company has not asked its Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether its Sponsor has sufficient funds to satisfy its indemnity obligations and believe that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that its Sponsor would be able to satisfy those obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity, Capital Resources and Going Concern</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s liquidity needs up to February 11, 2021, the date of the IPO, had been satisfied through a capital contribution from the Sponsor of $25,000 (see Note 5) for the founder shares and the loans under an unsecured promissory note from the Sponsor of $73,295 (see Note 5). In order to finance transaction costs in connection with a Business Combination, the Company’s Sponsor or an affiliate of the Sponsor or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s IPO was on February 11, 2021. As of December 31, 2022, the Company had $67,909 in its operating bank account, and working capital deficit of $2,874,594 (excluding taxes payable which is funded by earnings from the Trust Account) and has incurred and expects to incur additional significant costs in pursuit of its financing and acquisition plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Additionally, the Company has until August 11, 2023 (originally February 11, 2023; see Note 10) to consummate a Business Combination. In connection with the Company’s assessment of going concern considerations in accordance with FASB ASC Topic 205-40, “Presentation of Financial Statements– Going Concern,” Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution raises substantial doubt about the Company’s ability to continue as a going concern. The Company intends to complete a Business Combination before the mandatory liquidation date. No adjustments have been made to the carrying amounts of assets or liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p>
CY2022 pmgmu Condition For Future Business Combination Number Of Businesses Minimum
ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum
1
CY2022Q4 pmgmu Transaction Costs
TransactionCosts
15630212
CY2022Q4 pmgmu Sale Of Stock Underwriting Fees
SaleOfStockUnderwritingFees
5520000
CY2022Q4 pmgmu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
9660000
CY2022Q4 pmgmu Sale Of Stock Other Offering Costs
SaleOfStockOtherOfferingCosts
450212
CY2022Q4 pmgmu Transaction Costs Included In Operation Statement
TransactionCostsIncludedInOperationStatement
655046
CY2022Q4 pmgmu Transaction Costs Included In Equity Statement
TransactionCostsIncludedInEquityStatement
14975165
CY2022 pmgmu Investments Maximum Maturity Term
InvestmentsMaximumMaturityTerm
P185D
CY2022 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination After Extension
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombinationAfterExtension
P24M
CY2022 pmgmu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2022 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination After Extension
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombinationAfterExtension
P24M
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10.00
CY2022 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination After Extension
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombinationAfterExtension
P24M
CY2022 pmgmu Maximum Allowed Dissolution Expenses
MaximumAllowedDissolutionExpenses
100000
CY2022Q4 pmgmu Cash At Operating Bank Account
CashAtOperatingBankAccount
67909
CY2022Q4 pmgmu Working Capital Deficit
WorkingCapitalDeficit
-2874594
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p>
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
68000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
497000
CY2022 pmgmu Investments Maximum Maturity Term
InvestmentsMaximumMaturityTerm
P185D
CY2022 pmgmu Transaction Costs Allocated To Public Warrants
TransactionCostsAllocatedToPublicWarrants
655046
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
276000000
CY2021 pmgmu Temporary Equity Proceeds Allocated To Warrants
TemporaryEquityProceedsAllocatedToWarrants
-11408000
CY2021 pmgmu Common Stock Issuance Costs
CommonStockIssuanceCosts
-14975165
CY2021 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
26383165
CY2021Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
276000000
CY2022 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
2487272
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
278487272
CY2022 pmgmu Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.081
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022 pmgmu Advance Notice Prior To Applicable Deadline Affiliates Or Designees Must Deposit Into Trust Account
AdvanceNoticePriorToApplicableDeadlineAffiliatesOrDesigneesMustDepositIntoTrustAccount
P30D
CY2022 pmgmu Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination
PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination
1
CY2022 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombination
P18M
CY2022 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination After Extension
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombinationAfterExtension
P24M
CY2022 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombination
P18M
CY2022 pmgmu Threshold Period From Closing Of Proposed Public Offering To Consummate Initial Business Combination After Extension
ThresholdPeriodFromClosingOfProposedPublicOfferingToConsummateInitialBusinessCombinationAfterExtension
P24M
CY2022Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
150000
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0
CY2022 pmgmu Maximum Borrowing Capacity Of Related Party Promissory Note
MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
300000
CY2021 pmgmu Maximum Borrowing Capacity Of Related Party Promissory Note
MaximumBorrowingCapacityOfRelatedPartyPromissoryNote
266964
CY2022Q4 pmgmu Deferred Fee Per Unit
DeferredFeePerUnit
0.35
CY2022Q4 pmgmu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
9660000
CY2022Q4 pmgmu Gain On Reduction In Deferred Underwriting Fee Payable
GainOnReductionInDeferredUnderwritingFeePayable
3767400
CY2022Q4 pmgmu Deferred Underwriting Compensation Noncurrent
DeferredUnderwritingCompensationNoncurrent
5892600
CY2021Q4 pmgmu Deferred Underwriting Compensation Noncurrent
DeferredUnderwritingCompensationNoncurrent
9660000
CY2022Q4 pmgmu Maximum Number Of Demands For Registration Of Securities
MaximumNumberOfDemandsForRegistrationOfSecurities
3
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 pmgmu Initial Business Combination Shares Issuable As Percent Of Outstanding Share
InitialBusinessCombinationSharesIssuableAsPercentOfOutstandingShare
0.01
CY2022Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
669759
CY2021Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
7384800
CY2022Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
279384429
CY2022 pmgmu Interest Income From Assets Held In Trust Account
InterestIncomeFromAssetsHeldInTrustAccount
401925
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
276079687
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25360
CY2022Q4 pmgmu Deferred Tax Assets Capitalized Start Up And Organization Costs
DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts
1231442
CY2021Q4 pmgmu Deferred Tax Assets Capitalized Start Up And Organization Costs
DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts
364454
CY2022Q4 pmgmu Deferred Tax Asset Unrealized Gain Loss On Trust
DeferredTaxAssetUnrealizedGainLossOnTrust
-588900
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
642542
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.077
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.047
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.081
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
389814
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1231441
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
389814
CY2022Q4 pmgmu Current Deferred Tax Liabilities
CurrentDeferredTaxLiabilities
588899
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
230537
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-119370
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-389814
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
63893
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-133358
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
841627
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
389814
CY2022 pmgmu Income Tax Provision
IncomeTaxProvision
883329
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
841627
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
389814
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.055
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.000
CY2022 pmgmu Effective Income Tax Rate Reconciliation Tax Credit State Percent
EffectiveIncomeTaxRateReconciliationTaxCreditStatePercent
-0.001
CY2021 pmgmu Effective Income Tax Rate Reconciliation Tax Credit State Percent
EffectiveIncomeTaxRateReconciliationTaxCreditStatePercent
0.000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.009
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2022 pmgmu Effective Income Tax Rate Reconciliation Deduction Acquisition Expenses Percent
EffectiveIncomeTaxRateReconciliationDeductionAcquisitionExpensesPercent
0.005
CY2021 pmgmu Effective Income Tax Rate Reconciliation Deduction Acquisition Expenses Percent
EffectiveIncomeTaxRateReconciliationDeductionAcquisitionExpensesPercent
0.000
CY2022 pmgmu Effective Income Tax Rate Reconciliation Deduction Penalties And Interest Percent
EffectiveIncomeTaxRateReconciliationDeductionPenaltiesAndInterestPercent
0.000
CY2021 pmgmu Effective Income Tax Rate Reconciliation Deduction Penalties And Interest Percent
EffectiveIncomeTaxRateReconciliationDeductionPenaltiesAndInterestPercent
0.000
CY2022 pmgmu Effective Income Tax Rate Reconciliation Nondeductible Expense Offering Costs Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfferingCostsAmount
0.000
CY2021 pmgmu Effective Income Tax Rate Reconciliation Nondeductible Expense Offering Costs Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfferingCostsAmount
0.017
CY2022 pmgmu Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability Percent
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent
-0.164
CY2021 pmgmu Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liability Percent
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilityPercent
-0.274
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
pmgmu-20221231_lab.xml Edgar Link unprocessable
0001104659-23-023947-index-headers.html Edgar Link pending
0001104659-23-023947-index.html Edgar Link pending
0001104659-23-023947.txt Edgar Link pending
0001104659-23-023947-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pmgmu-20221231.xsd Edgar Link pending
pmgmu-20221231x10k.htm Edgar Link pending
pmgmu-20221231xex31d1.htm Edgar Link pending
pmgmu-20221231xex31d2.htm Edgar Link pending
pmgmu-20221231xex32d1.htm Edgar Link pending
pmgmu-20221231xex32d2.htm Edgar Link pending
pmgmu-20221231xex3d1a.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
pmgmu-20221231_cal.xml Edgar Link unprocessable
pmgmu-20221231_def.xml Edgar Link unprocessable
pmgmu-20221231_pre.xml Edgar Link unprocessable
pmgmu-20221231x10k_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending